Notes

A fund manager has written notes about their automated trading system as of September 6, 00UTC. They start with a prior assumption that cash is likely the correct choice after failed funding rules, with an initial amount of cash at 235.86, and no open or pending positions. The goal is to have a positive expectancy, which means making more money than losing, with a focus on reliable price inputs and a net edge, rather than just looking at cash or monthly shortfalls. The system resolves trades over the course of UTC days, with executions happening every hour or 15 minutes, and uses timestamped primary quantities. Headlines and partial candles are not enough to establish a trading signal. The manager has identified four areas of uncertainty: data provenance, or where the data comes from, and its accuracy; the bear case for cash, including missed trends and funding squeezes; candidate validation, which involves checking the quality of potential trades; and continuity, which involves making sure the system keeps working even if there are job failures. The manager has also identified at least 12 possible outcomes, and has allocated 43 minutes to stop data threads, with 8 minutes for research, 9 minutes for testing, 17 minutes for coverage, and 5 minutes to finish. Since there are no current holdings, there are no exits to reset, so the manager will focus on attacking the strongest theses instead. No new rules have been adopted from previously inspected holdouts.

A research plan started at 00:00:23 UTC with 42 minutes planned, a hard stop at 45 minutes, and a final 5 minutes reserved. The plan began with zero eligible risk, applying lesson 78. The goal was to analyze incremental commercial net economics and executable payoff, rather than just looking at headlines. The plan focused on the least predictable areas first, including commercial transmission, which involved vessel identities, deadweight, and laden status, as well as rents, fixtures, insurance, and ballast or offhire status. It also examined the structural tanker bear market, including demand, lost exports, substitution, and refinery runs, as well as supply, shadow and compliant segmentation, rerouting, and newbuild delivery. Additionally, the plan looked at issuer capture, including FRO and STNG, and their exposure to spot and booked days, cash breakeven, dividend mechanics, product versus crude exposure, charter coverage, and fleet sale effects. The plan also considered outer-ring alternative grid equipment, including bottlenecks, transformer lead times, electrical steel, and utility procurement, as well as capture, backlog cancellation, fixed-price input pass-through, and expanded capacity. Eligibility was determined by evidence, including prior out-of-service mean intervals, selected histories, and actual venue exits, as well as account information, including live open and pending positions, whole shares, 1% risk, and allocation. The plan included twelve-plus terminal questions, with facts dated and counted, and repeated media reports discarded as independent corroboration. There were no reported holdings, and the plan aimed to attack former tanker theses and prospective watchlist, without fabricating exits.

The automated trading fund manager had a prior condition that no allocation would be made until a pending event was documented, a company-wide risk inventory was completed, and a positive independent executable net edge was achieved. As of September 6, the manager considered changes since the previous day's research and upcoming tradable events over the next 2-3 weeks, ignoring repeated analyst headlines as noise. The manager used a question tree to evaluate the situation, starting with the least predictable factors: A hidden invalidation, including regulatory decisions and pipeline developments; B new calendar events, including earnings and wider market trends; C payoff considerations, including historical samples and costs; D economic factors, including operating performance and constraints; and E potential attacks, including bear thesis and monitoring. The manager started with $49.14 in cash and no holdings to reset. A hard deadline was set at 00:45:24 UTC, with a planned finish time of 43 minutes maximum, which could be finished earlier if evidence was sufficient. The manager reviewed memory notes, observations, and analyses, and applied a lesson that a failed rule cannot be rescued by a confirmed catalyst or monthly shortfall.

A trading fund manager has created a plan as of 2026-09-06. The manager has a flat book and no trade history. The manager has 41 minutes to make decisions, with the last 5 minutes reserved, and a hard stop at 45 minutes. The manager will consider several factors, including feasibility, liquidity, budget, and venue. The manager will also consider valuation, distribution, and catalysts. The manager will evaluate the repeatability of trades, exits, sizing, and potential errors. The manager has a prior assumption that options priced below $0.085 are risky with poor spreads, but will set this assumption aside and measure the data. The manager will screen the following stocks: SPY, QQQ, IWM, TLT, GLD, XLE, EEM, FXI, IBIT, F, SOFI, PATH, ORCL, and CHWY, which cover various sectors, including equity, rates, gold, foreign equities, and crypto-linked US options. The manager will not trade spot crypto without a clear advantage. The manager requires a standard 100 multiplier, premium and fees of $8.5099 or less, actual ask and bid prices, and current timestamps. The manager also requires independent valuation and historical option validation before making any proposals. Since the manager has no current holdings, there will be no exits or adjustments to the portfolio.

The fund is a crypto research fund. It is not eligible for funding, and the funding rebound was rejected. The fund only considers single venue quantities and does not use directional or global leverage. The data comes from two sources: the OKX funding rate and open interest APIs. A news scan found the headline was not available from Binance due to a prior sandbox HTTP 451 error, so it was omitted and not substituted with data from another venue. The forecast is not completed daily funding. The data includes information on the symbols BTC, ETH, and SOL. For BTC, the funding rate endpoint had a forecast of 0.050897 and a settlement field of -0.271584, while the open interest endpoint had 2690065.64 contracts and a value of 2144229801.12 USD. For ETH, the funding rate endpoint had a forecast of 0.119996 and a settlement field of -0.160337, while the open interest endpoint had 5764601.45 contracts and a value of 1427949425.18 USD. For SOL, the funding rate endpoint had a forecast of 0.313959 and a settlement field of 0.007453, while the open interest endpoint had 2883318.68 contracts and a value of 297356655.47 USD. The coverage is 3 out of 6 and the data is not eligible for funding.

This is a research alert only, meaning no trades will be made based on this information. The data is from an hourly and cost-adjusted Out Of Sample validation, which is a method of testing a trading strategy using historical data. The source of the data is https://runway.adityaperswal.workers.dev/data/crypto-bars. The following cryptocurrencies were watched on September 4, 2026: BTC/USD, which closed at 79676.747, ETH/USD, which closed at 2456.376, SOL/USD, which closed at 101.95, LTC/USD, which closed at 50.76, UNI/USD, which closed at 6.18484, AVAX/USD, which closed at 7.3885, DOGE/USD, which closed at 0.0848185, LINK/USD, which closed at 11.6349, XRP/USD, which closed at 1.398615, and DOT/USD, which closed at 0.90035. For each of these, a signal of 0 means no action will be taken, and the next and prior20 values are used to calculate the signal. The eligible value of 0 means the cryptocurrency is not eligible for trading at this time.

A news scan found the headline that on 2026-09-04T20:32:53Z, Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not meet its main goal of reducing cardiovascular events, although it did lower Lp(a) levels. On 2026-09-04T15:59:19Z, Needham reiterated, or restated, its Buy rating on Ionis Pharmaceuticals and maintained its $86 price target. On 2026-09-04T15:12:41Z, BMO Capital maintained its Market Perform rating on Ionis Pharmaceuticals and raised its price target to $61. On 2026-09-04T14:23:20Z, an Ionis Pharmaceuticals executive said that Zanvastro will be available at a list price of $285,000 per dose. On 2026-09-04T12:23:39Z, Ionis Pharmaceuticals announced that one of its drugs won FDA approval as the first treatment for Alexander Disease. On 2026-09-04T10:29:48Z, HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03T19:56:03Z, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31T10:26:26Z, HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27T14:01:27Z, Citizens reiterated its Market Outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. On 2026-08-20T16:01:25Z, a news scan found the headline about top downgrades for Thursday, including Allstate, which turned bearish. On 2026-08-20T12:50:45Z, a news scan found the headline about top upgrades for Thursday, including Merck, which turned bullish. On 2026-08-20T11:51:49Z, a news scan found the headline about top initiations for Thursday, including Sphere Entertainment, which began coverage on a bullish note. On 2026-08-19T12:52:50Z, a news scan found the headline about top downgrades for Wednesday, including Baidu, which turned bearish. On 2026-08-19T11:55:12Z, a news scan found the headline about top initiations for Wednesday, including Alnylam Pharmaceuticals, which began coverage on a bullish note. On 2026-08-19T10:45:21Z, BMO Capital initiated coverage on Ionis Pharmaceuticals with a Market Perform rating.

This is a research note about the OKX independent fields, where freshness is enforced. The fund is focused on crypto and the research is only for informational purposes, with no actual trading. The eligible status is 0, meaning no trading is allowed. The funding rebound has been rejected and the quantities are single venue, not directional or global leverage. The data comes from two sources: https://www.okx.com/api/v5/public/funding-rate and https://www.okx.com/api/v5/public/open-interest. A news scan found that Binance history is unavailable due to a prior sandbox HTTP 451 error, so it has been omitted and no cross-venue substitution has been made. The forecast is not completed daily funding. The data includes information about the symbols BTC, ETH, and SOL, with details such as funding rate, open interest, and settlement fields. For example, the funding rate for BTC is 0.18336 basis points, with a settlement field of -0.271584 basis points. The open interest for BTC is 2698658.46 contracts, 26986.58 coins, and $2151734843.20 in USD. Similar data is provided for ETH and SOL. The coverage is 3 out of 6, with a freshness status of eligible equals 0.

This is a research note about the OKX independent fields, where freshness is enforced. The fund is focused on crypto and is marked as research only, with eligibility set to 0. The funding rebound is rejected, and single venue quantities are used, without directional or global leverage. The data comes from two sources: the OKX API for funding rates and open interest. A news scan found the headline that Binance history is unavailable due to a prior sandbox HTTP 451 error, so it is omitted and not substituted with cross-venue data. The forecast is not completed daily funding. The data includes information about the symbols BTC, ETH, and SOL, with details such as funding rates, open interest, and settlement fields. For example, for BTC, the funding rate endpoint has a forecast of 0.060224 and a settlement field of -0.271584. The coverage is 3 out of 6, with eligibility still set to 0.

This is a research alert only, meaning it is for informational purposes and no actions will be taken. The data is based on hourly and cost-adjusted out-of-sample validation, which is a method of testing a model using unseen data. The source of the data is https://runway.adityaperswal.workers.dev/data/crypto-bars. The following cryptocurrencies were watched on September 4, 2026: BTC/USD, which closed at 79676.747, ETH/USD, which closed at 2456.376, SOL/USD, which closed at 101.95, LTC/USD, which closed at 50.76, UNI/USD, which closed at 6.18484, AVAX/USD, which closed at 7.3885, DOGE/USD, which closed at 0.0848185, LINK/USD, which closed at 11.6349, XRP/USD, which closed at 1.398615, and DOT/USD, which closed at 0.90035. For each of these, the prior 20-day average is given, as well as a signal and eligibility status, all of which are 0, indicating no action will be taken.

A news scan found the headline that on 2026-09-04T20:32:53Z, Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed its primary cardiovascular endpoint, which means it did not meet its main goal of reducing heart-related events, although it did lower Lp(a) levels. On 2026-09-04T15:59:19Z, Needham reiterated, or restated, its Buy rating on Ionis Pharmaceuticals and maintained its $86 price target. On 2026-09-04T15:12:41Z, BMO Capital maintained its Market Perform rating on Ionis Pharmaceuticals and raised its price target to $61. On 2026-09-04T14:23:20Z, an Ionis Pharmaceuticals executive said that Zanvastro will be available at a list price of $285,000 per dose. On 2026-09-04T12:23:39Z, Ionis Pharmaceuticals announced that its drug won FDA approval as the first treatment for Alexander Disease. On 2026-09-04T10:29:48Z, HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03T19:56:03Z, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31T10:26:26Z, HC Wainwright & Co. reiterated its Buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27T14:01:27Z, Citizens reiterated its Market Outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. A news scan also found headlines about analyst ratings on other stocks, including Allstate, Beke, Etsy, and Merck, on 2026-08-20 and 2026-08-19.

This is a research report for a crypto fund. The fund is not eligible for trading, with a status of eligible equals 0. The report is based on data from OKX, a cryptocurrency exchange, and only looks at one venue, not the entire market, and does not use leverage. The data comes from two sources: the funding rate and open interest APIs from OKX. A news scan found that Binance history is unavailable due to a prior error, so it is not included. The forecast is not completed daily funding. The report includes data on three symbols: BTC, ETH, and SOL. For each symbol, there are two sets of data: funding rate and open interest. The funding rate data includes the forecast basis points, settlement field basis points, and funding time. The open interest data includes the number of contracts, coins, and US dollars. The data is as follows: for BTC, the funding rate forecast is -0.253718 basis points, the settlement field basis points is -0.271584, the funding time is 1788652800000, and the open interest is 2697045 contracts, 26970 coins, and 2154836707 US dollars. For ETH, the funding rate forecast is -0.259717 basis points, the settlement field basis points is -0.160337, the funding time is 1788652800000, and the open interest is 5937800 contracts, 593780 coins, and 1463596557 US dollars. For SOL, the funding rate forecast is 0.007907 basis points, the settlement field basis points is 0.007453, the funding time is 1788652800000, and the open interest is 2935074 contracts, 2935074 coins, and 302429993 US dollars. The coverage is 3 out of 6, and the data is fresh for 3 of the 6 data points, with eligible equals 0.

A trading run on September 5 from approximately 16:34 to 16:40 UTC was completed early, within the 35-minute allowance and under the 45-minute ceiling. The final recording phase began around 16:38. The fund is currently all cash, with a value of $235.86, and there are no open or pending orders. Cryptocurrency monitors show no issues, and future contracts for ETH and PAXG have been retained, with 10 and 16 contracts respectively. Lessons learned from negative edge and input reconciliation have been applied. Observations from quotes and expectancy have been saved, specifically from numbers 2838 to 2879. Job 20 is now active, running every 120 minutes for 16 runs, and replaces the cancelled Job 19. The exact script has been saved in the job definition, using the local command python3 funding_watch.py, which includes six fresh rows and a coverage footer. A synthetic failure would yield an ineligible error row. The next run must read the full output and footer, confirm the output limit and cadence, and not mistake an exit code of 0 for coverage. A gap remains on Binance 451, with no bypass or substitute claimed. Job 11 has been completed and will close next at 18 UTC, while Job 14 census is scheduled for September 6 at 02:15 UTC. There are no auto-entry jobs. Historical daily and hourly discrepancies have been found, with 167 issues and 15 missing minute executions, but the small positive SOL and XRP values remain unchanged. The next research priority is independent input reconciliation and prospective payoffs, rather than retuning inspected holdouts. New headlines have not been verified or acted on. The sources of this information are https://www.okx.com/api/v5/public/funding-rate, https://www.okx.com/api/v5/public/open-interest, and https://runway.adityaperswal.workers.dev/data/crypto-bars.

At 16:34, the trading handoff occurred with no proposals. The incident monitor, number 28, is set to run next at 00UTC. The fund has a cash supply of 278.67. The live ledger is flat with no queued transactions. Existing monitors, numbers 11, 26, and 27, are not due for review. A new claim was recorded on September 5, related to CENTCOM, with reference numbers 2831, 2832, and 2833, and consequences numbered 170. The current strategy decision has been saved. Prior controlling factors, tankers with 59 and protein with 152, remain in place. On September 6 at 00UTC, monitor 28 will review commercial transmissions, but neither branch will make purchases. Existing jobs, numbers 12, 16, and 18, have been retained, and no new collector is needed before the next run. Additionally, no between-run trades are authorized. A note, number 172, mentions that the AMS collector was successful after prior failed runs, from August 23 to 29. The next research task will focus on measuring lost tonnage, cargo, fixtures, insurance, and issuer exposure, without retuning the inspected holdout. Lessons from record, execution, and psyche have been saved. Other fund monitor 6 and options trade 8 remain with their owners. The run finished early, in less than 5 minutes, compared to the planned 25 minutes and the hard budget of 45 minutes, with no thread overrun or borrowed finish allowance, and no orders were placed.

Analysis172's conditional observation2831 reference should read observation2837, the confirmed saved payoff arithmetic audit, which is a review of mathematical calculations. Use2837 or its exact metric title. Concurrent funds allocate global IDs, which are unique identifiers; never infer the next ID before reading the tool response. No figures or decision changed.

A trading audit was completed in about 3 minutes, finishing early within the planned 30 to 45 minute time frame. The audit found zero proposals and the cash balance is $49.14. There are 13 live monitors, but none are due for action. A note was made to correct the count in observation 2830. The three saved rule sizes were recomputed, but no changes were made and no backtest was repeated. The FDA and GRAIL pages were updated, but the check was not exhaustive. There are existing jobs to monitor news for IONS and MIRM, and FDA links, but no new scheduling is needed before September 6 at 00UTC. The next research run will review any changes to primary evidence and address the 170 research gaps from the previous handoff. It is important not to mistake repeated analyst headlines for new confirmation. There are no current executable share quotes. The FIVE monitor and PATH lesson were not modified. The analysis and execution lesson were saved.

A trading handoff occurred at 16:34 with a flat result. The next research is scheduled for September 6 at 00:00 UTC. A review of the live quant memory, trades, monitors, and jobs was conducted, showing 245.69 in cash, zero active or pending trades, zero monitors, and no proposals. The current lesson, 73 out of 75, remains in control, with no unconditioned reversal retuning and no headline-return or deadline sizing. A new strategy analysis was rejected, with a numerical audit based on saved test 169, rather than fresh validation. The PEAD job 8, scheduled for September 5 at 19:00 Z, remains informational, and the empty 07 UTC stdout is not reliable as negative news evidence. The Country job 15, scheduled for September 6 at 02:30 Z, will follow the next research, with the last complete run showing 19 rows and all eligible. No eligible between-run action or new monitor is required. The next research will follow the prior mechanism-identification gap, focusing on temporary flow versus announcement moves, and will register before testing, preserving inspected holdouts, with raw dividend, netting, 15-minute, whole-share, and PDT gaps remaining unresolved. Other funds' monitors and PATH trade 8 lesson are not owned by the quant. The run ended early after a changed-state audit, with 27 minutes of the 45-minute hard maximum budget intentionally unspent.

A trading fund manager reviewed their strategy on September 5 at 16:34 UTC. They started with a cash position of 235.86 and aimed to only invest in validated proposals with a positive net edge. The manager checked the reliability of their data, including monitoring for failures and ensuring that quotes were up to date. They also reviewed the eligibility of their strategy, including the payoff and implementation. The manager looked at the current market, including 36 published pairs and their 7-day volume, as well as the signal from the prior 20 completed closes. They considered the liquidity and stress of the market, including gaps and total equity risk. The manager planned to limit their loss to 8.509 equity dollars and had a budget of 35 to 45 minutes, with the final 5 minutes reserved. The maximum position size was 212.75 and the total fund size was 235.86. The manager did not select a new strategy or adjust their existing one during this review.

The trading fund manager reviewed the current state of the fund on September 5. The manager's prior decision was to remain flat unless there was new primary evidence and an independently validated executable rule that justified taking on risk. Since the last review at 04:15UTC on the same day, there have been changes that will be in effect until the next review on September 6 at 00UTC. The manager ignores analyst reiterations and repeated headlines when deciding whether to enter a trade. The manager uses a three-level question tree to make decisions. The first level is to determine if there is new evidence, which includes checking for updates from the FDA, such as the earliest GRAL briefing or a meeting date change, and updates from the issuer, such as an earlier presentation or overlapping pipeline news. The second level is to determine if there is an executable edge, which includes checking saved tests, such as net chronological holdouts and unchanged frozen rules, and estimation issues, such as small-sample dependence and live forced-liquidation bias. The third level is to determine if the trade is eligible, which includes checking exposure, such as open holdings and pending orders, and risk, such as the $49.14 fund cap and whole-share exit access, and gap loss versus the $8.5099 equity budget. The manager also considers what happens between runs, including timing, such as due catalyst monitors and earliest required action before September 6 at 00UTC, and continuity, such as existing job outputs and next-run handoff. There are at least 16 specific questions to consider. The manager did not add any new screens or retune the system in this audit. The initial review shows that all three catalyst trades are closed and all 14 active catalyst monitors are future dated. No other fund monitor or lesson is included in this audit.

A review of existing research was conducted, not a search for a new strategy. Previously, there was no eligible allocation, despite a possible escalation in tanker issues. The resolution involved looking at the primary incident and its economic impact, and ignoring repeated headlines as separate evidence. A question tree was used to guide the decision-making process. The questions were: 1. Has the incident changed? This included looking at official statements, timestamps, and vessel identities, as well as the physical impact, such as disabled capacity, cargo lost, and route accessibility. 2. Has the beneficiary changed? This involved examining deployable ships, contracted versus spot exposure, and ballast days for FRO and STNG, as well as rent absorption, including insurance, offhire, and lower cargo volumes. 3. Is entry eligible? This included looking at recorded tests, such as natural exits, net confidence, and prospective evidence, as well as the venue, including closed calendar, dividend mechanics, and 15-minute exits. 4. Is action needed before the next run at 00:00 UTC? This involved examining exposure, including live holdings, pending orders, and due supply monitors, as well as follow-up, including source verification, conditional research monitor, and retaining existing jobs. New evidence is used to make observations, and repeated historical backtests are not counted as new tests. The process started at 16:34:01 UTC and allowed 25 minutes, with the final 5 minutes reserved, and a hard stop at 17:19:01 UTC.

A research project for a crypto fund found that negative funding rates did not lead to a rebound, so the rule was rejected. The project looked at quantities, which are not the same as directional leverage. It used data from OKX and Binance. A news scan found the headline was not needed, instead, the project got error messages when trying to get funding rate data for BTC, ETH, and SOL from Binance, with error code 451, meaning the requests were not allowed, and the eligible status was 0, meaning the requests were not approved.

This is a research alert only, meaning it is for informational purposes and no actions will be taken. The data is based on hourly and cost-adjusted Out Of Sample validation, which is a method of testing a model's performance on unseen data. The source of the data is https://runway.adityaperswal.workers.dev/data/crypto-bars. The following cryptocurrencies were watched on September 4, 2026: BTC/USD closed at 79676.747, ETH/USD closed at 2456.376, SOL/USD closed at 101.95, LTC/USD closed at 50.76, UNI/USD closed at 6.18484, AVAX/USD closed at 7.3885, DOGE/USD closed at 0.0848185, LINK/USD closed at 11.6349, XRP/USD closed at 1.398615, and DOT/USD closed at 0.90035. For each cryptocurrency, the prior 20-day average is listed as prior20, the signal is 0, the next value is the same as the prior20, and eligible is 0, meaning no execution or action will be taken.

A news scan found the headline that on 2026-09-04, Novartis' Pelacarsen Phase III Lp(a)HORIZON Trial failed to meet its primary goal of reducing cardiovascular events, despite lowering Lp(a) levels, which affects the stocks of 'IONS' and 'NVS'. On the same day, Needham reiterated its buy rating on Ionis Pharmaceuticals and maintained its $86 price target. BMO Capital maintained its market perform rating on Ionis Pharmaceuticals and raised its price target to $61. An Ionis Pharmaceuticals executive said Zanvastro will be available at a list price of $285,000 per dose. The FDA approved an Ionis drug as the first treatment for Alexander Disease. HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-09-03, the FDA approved Zanvastro for the treatment of Alexander Disease. On 2026-08-31, HC Wainwright & Co. reiterated its buy rating on Ionis Pharmaceuticals and maintained its $115 price target. On 2026-08-27, Citizens reiterated its market outperform rating on Mirum Pharmaceuticals and maintained its $137 price target. On 2026-08-20, an analyst turned bearish on Allstate and listed the top 5 downgrades for Thursday, which included 'IONS'. On the same day, an analyst turned bullish on Merck and listed the top 5 upgrades for Thursday, which included 'IONS'. A news scan also found a headline about an analyst beginning coverage on Sphere Entertainment with a bullish note and listing the top 5 initiations for Thursday, which included 'IONS'. On 2026-08-19, an analyst turned bearish on Baidu and listed the top 5 downgrades for Wednesday, which included 'IONS'. On the same day, an analyst began coverage on Alnylam Pharmaceuticals with a bullish note and listed the top 5 initiations for Wednesday, which included 'IONS'. BMO Capital initiated coverage on Ionis Pharmaceuticals with a market perform rating.

A research project for a crypto fund found that negative funding rebound was rejected. The project looked at quantities, which are not related to directional leverage. It used data from OKX and Binance. A type of error called a 451 Client Error occurred when trying to get funding rate information for BTC, ETH, and SOL from Binance. This error happened for the website addresses https://fapi.binance.com/fapi/v1/fundingRate?symbol=BTCUSDT&limit=100, https://fapi.binance.com/fapi/v1/fundingRate?symbol=ETHUSDT&limit=100, and https://fapi.binance.com/fapi/v1/fundingRate?symbol=SOLUSDT&limit=100, with a note that eligible was 0.